Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 132 matching trials from the live ClinicalTrials.gov search.
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women

NCT01894581
Conditions
Obesity, Fertility
Interventions
LOVAZA, GnRH
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions
Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo
Dietary Supplement · Combination Product · Other
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more
Conditions
Colorectal Adenomatous Polyps
Interventions
Eicosapentanoic acid and docosahexanoic acid, Oleic Acid
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years to 79 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions
Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 74 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Kansas City, Kansas • Ann Arbor, Michigan • Columbus, Ohio
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Healthy Volunteers, Markers of Cardiovascular Risk
Interventions
SDA soybean oil-containing foods, High-oleic sunflower oil containing foods, Eicosapentaenoic acid
Other
Lead sponsor
Monsanto Company, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Addison, Illinois
Conditions
Hypertriglyceridemia
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Results available

Lovaza® and Microvascular Function in Type 2 Diabetes

NCT00931879
Conditions
Hypertriglyceridemia, Diabetic Neuropathy
Interventions
omega-3-ethyl esters, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia

NCT01048502
Conditions
Cardiovascular Disease
Interventions
Fenofibrate (Tricor) tablets, Placebo, Lovaza
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Results available

Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome

NCT01107964
Conditions
Dry Eye Syndrome
Interventions
Oral Omega-3-acid ethyl esters, Placebo corn oil capsule
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Completed Not applicable Interventional

Breast, Omega 3 Free Fatty Acid, Ph 0

NCT02996240
Conditions
Breastcancer
Interventions
Omega-3 FFA
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Bone Density, Bone Health, Fractures
Interventions
Vitamin D3 placebo, Fish oil placebo, Omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Coronary Heart Disease, Metabolic Syndrome
Interventions
Omega 3 acid ethyl esters
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Milton, Massachusetts
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Omega-3 Fatty Acids and Insulin Sensitivity

NCT01686568
Conditions
Insulin Resistance
Interventions
Omega-3, placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Stimulants plus Lovaza, Stimulants plus placebo
Dietary Supplement · Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
6 Years to 15 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Cardiovascular Disease, HIV Infection
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

NCT00723398
Conditions
Breast Cancer
Interventions
Lovaza 4gm oral, Raloxifene 60 Mg Oral Tablet, Raloxifene 30 Mg Oral Tablet, Lovaza 4gm & Raloxifene 30mg
Dietary Supplement · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
266 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Completed Phase 4 Interventional Results available

Niacin, N-3 Fatty Acids and Insulin Resistance

NCT00286234
Conditions
Metabolic Syndrome, Hypertriglyceridemia
Interventions
omega-3 acid ethyl esters, extended release niacin, placebo, combined treatment
Drug
Lead sponsor
University of South Dakota
Other
Eligibility
40 Years to 69 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Conditions
Coronary Artery Disease
Interventions
Omacor (omega-3-acid ethyl esters)
Drug
Lead sponsor
Olive View-UCLA Education & Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Sylmar, California
Conditions
HIV Infections, Heart Disease
Interventions
Lovaza, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Lung Diseases, Lung Cancer, Protection Against
Interventions
Curcumin C3 complex®, Lovaza®, Placebo
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery

NCT00446966
Conditions
Atrial Fibrillation
Interventions
Omega Three Polyunsaturated fatty acids
Drug
Lead sponsor
Chirag Sandesara
Other
Eligibility
18 Years to 85 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Bipolar Disorder
Interventions
Ethyl Eicosapentaenoic Acid
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin